Sage Journals: Discover world-class research

Abstract

Background

Psoriasis is a chronic disease with increased risk of numerous comorbidities. Known differences exist regarding treatment outcomes for psoriasis patients with skin of color (SOC). Factors contributing to these differences are relatively unknown.

Objectives

This study aims to compare the comorbidity burden in SOC psoriasis patients vs White patients, as measured by the Charlson Comorbidity Index (CCI).

Methods

We utilized the National Ambulatory Medical Care Survey (NAMCS) to identify visits for adult psoriasis patients occurring in the years 2002-2016 and 2018. The CCI was used to objectively measure comorbidity burden. Patients were identified by race, and SOC was defined as any reported race besides White Only. A multiple linear regression was run to compare the CCI among adult psoriasis patients based on race and ethnicity, controlling for age, sex, insurance status, and geographic region.

Results

A total of 39, 176, 928 weighted visits were analyzed. Compared to White patients, patients with SOC did not have statistically significant differences in comorbidity burden, as measured by CCI (P = .073 for Black/African American Only vs White Only, P = .073 for American Indian/Alaska Native Only vs White Only, P = .435 for Asian Only vs White Only, P = .403 for Native Hawaiian/Pacific Islander Only vs White Only, P = .195 for Other vs White Only).

Conclusion

Patients with SOC were not found to have differences in comorbidity burden compared to White patients. These results highlight that social factors such as socioeconomic status and access to health care may contribute more directly to psoriasis treatment outcomes than patient race.

Keywords

comorbidities epidemiology psoriasis race skin of color

Introduction

Psoriasis is a chronic disease that affects patients of various races and skin color.^1-3 Known differences exist regarding treatment outcomes for psoriasis patients with skin of color (SOC), with SOC patients reporting increased risk for hospitalization due to psoriasis and greater negative impact on quality of life.^4,5 Several possible explanations exist for this phenomenon. First, previous studies have suggested that dermatologists may underestimate the severity of psoriasis in patients with SOC due to differences in their cutaneous presentations compared to those in White patients.⁶ For example, psoriasis plaques may be mistaken for post-inflammatory hyperpigmentation on black skin.^4-6 Patients with SOC may be underrepresented in clinical trials for psoriasis.^4,5,7 Furthermore, differences in socioeconomic status, access to health care, and lack of culturally competent care may contribute to worse treatment outcomes for patients of different races and ethnicities.⁴ Psoriasis patients with SOC also report a significantly worse quality of life compared to White psoriasis patients.⁵ Thus, it is crucial to investigate possible differences in manifestations of psoriatic disease in order to optimize care for psoriasis patients with SOC.

One area that is understudied is the comorbidity burden that psoriasis patients of different races may experience. For example, 20%-30% of patients with psoriasis develop psoriatic arthritis, and some may also develop cardiovascular disease and depression.^1,8 However, little is known regarding differences in comorbidity burden based on patient race in psoriasis patients. This subject is important to study because potential differences in comorbidity burden based on race may contribute to patient outcomes. Here, the study aim was to compare the comorbidity burden in psoriasis patients with SOC vs White patients, as measured by the Charlson Comorbidity Index (CCI), to determine whether comorbidity burden differs based on race in psoriasis patients.

Methods

We performed a population-based, cross-sectional study to evaluate the comorbidity burden in psoriasis patients with SOC vs White patients. This study was classified “exempt” by the Institutional Review Board of the University of Southern California because it utilizes publicly available information provided by the Centers for Disease Control and Prevention. We utilized the National Ambulatory Medical Care Survey (NAMCS) to identify visits for adult psoriasis patients (≥18 years old) occurring from the years 2002 to 2016 and 2018. The NAMCS, administered by the Center for Disease Control, provides nationally representative samples of health care visits to physician offices and hospitals across the United States.⁹ Physicians were randomly selected and asked to collect information on practice and physician characteristics.¹⁰ The NAMCS utilizes a complex probability survey design with masked weighting variables to estimate a nationally representative sample of patient visits.⁹ For each patient visit, the NAMCS queries 3-5 free-entry patient diagnoses. In addition, the NAMCS specifically queries for other common comorbidities including Alzheimer’s disease, COPD, cancer, congestive heart failure, diabetes mellitus, and HIV/AIDS.

For this study, we identified patients with psoriasis by using the International Classification of Diseases, Ninth Revision (ICD-9) code 696.1 and the International Classification of Diseases, Tenth Revision (ICD-10) codes L40.0-L40.9. The CCI was selected as a method to objectively measure comorbidity burden. The CCI is a validated model for quantifying the mortality risk of patients by assigning a numerical score based on the presence or absence of 19 medical conditions.¹¹ This tool has proven to be useful for a variety of other purposes, including prognosis assessment for research purposes among different individuals with the same medical diagnosis.^12,13 Different conditions carry scores of either +1, +2, +3, or +6 if they are present: for example, conditions that are more chronic and less immediately life-threatening such as rheumatologic disease carry a score of +1, while more acute and immediately life-threatening diseases such as metastatic malignancy carry a score of +6.¹¹ Stepwise increases in CCI are associated with stepwise increases in comorbidities and patient mortality.¹³

The CCI was calculated for all outpatient visits for adult psoriasis patients, using previously established comorbidity codes from the ICD-9 and ICD-10.¹² In the NAMCS, adult patients with SOC were identified by their race as either Black/African American Only, Asian Only, Native Hawaiian/Pacific Islander Only, American Indian/Alaska Native Only, Multiracial, or Other. Adult White patients were defined by their race as White Only. A multiple linear regression was run to compare the CCI among adult psoriasis patients based on race and ethnicity, while adjusting for age, sex, geographic region, and insurance type. Sensitivity analyses were also run to evaluate the effect of insurance status on CCI for adult psoriasis patients based on race.

Results

Descriptive characteristics of the surveyed patient visits are listed in Table 1. Overall, a total of 39 176 928 (95% CI: 35 075 260-43 278 596) weighted visits were analyzed. The average age was 53.5 ± .6 (SEM) years old. There were 34 690 371 (95% CI: 30 872 464-38 508 278) weighted total outpatient visits for White Only patients (88.50%), 3 438 506 (95% CI: 1 905 843-4,971 168) weighted visits for Black/African American Only patients (8.78%), 750 821 (95% CI: 453 203-1,048 440) weighted visits for Asian Only patients (1.92%), 68 024 (95% CI: -4693-140,741) weighted visits for Hawaiian/Pacific Islander Only patients (.17%), 53 937 (95% CI: -23 181-131 056) weighted visits for American Indian/Alaska Native Only patients (.14%), and 175 268 (95% CI: 36 918-313 618) weighted visits for patients with race listed as Other (.45%).

Table 1.

Sociodemographic Characteristics of Psoriasis Patient Visits Between 2002-2016 and 2018 in NAMCS Database.

Characteristic	Overall Cohort visits	White only visits	Black/African american only visits	Asian only visits	Native Hawaiian/Pacific islander only visits	American indian/Alaska native only visits	Other visits	P Value
Characteristic	Weighted n = 39,176 928	Weighted n = 34,690 371	Weighted n = 3 438 506	Weighted n = 750 821	Weighted n = 68 024	Weighted n = 53 937	Weighted n = 175 268	P Value
Age, mean (SEM) years	53.5 (.6)	53.4 (.6)	55.7 (2.4)	45.8 (2.8)	44.8 (9.6)	66.5 (11.0)	48.4 (4.5)	.0462^a
Female sex, n (%)	20,426 501 (52.1)	18,072 317 (52.1)	1 833 480 (53.3)	301 662 (40.1)	66 601 (97.9)	54 848 (100)	94 025 (53.3)	.5446^b
Geographic region, n (%)
-Northeast	7 825 551 (23.0)	7 250 543 (23.7)	387 875 (16.6)	163 316 (21.7)	0 (.0)	0 (.0)	26 199 (14.8)	.0880^b
-Midwest	8 301 889 (24.4)	7 917 416 (25.8)	248 376 (10.6)	68 048 (9.0)	0(.0)	20 414 (37.5)	51 036 (28.8)
-South	11,051 039 (32.5)	9 543 770 (31.2)	1 272 503 (54.4)	153 109 (20.4)	47 634 (70.0)	0 (.0)	34 024 (19.2)
-West	6 845 656 (20.1)	5 923 602 (19.3)	435 509 (18.6)	370 863 (49.3)	20 414 (30.0)	33 344 (61.3)	61 243 (34.6)
Insurance, n (%)
-Private	24,334 067 (62.1)	21,637 498 (62.4)	1 805 736 (52.5)	650 222 (86.5)	47 004 (70.6)	54 838 (99.9)	137 095 (77.8)	.8133^b
-Medicare	9 112 808 (23.3)	8 147 356 (23.5)	885 241 (25.7)	32 903 (4.4)	20 368 (30.6)	0 (.0)	26 244 (14.9)
-Medicaid	2 692 708 (6.9)	2 342 365 (6.8)	317 277 (9.2)	34 078 (4.5)	0 (.0)	0 (.0)	0 (.0)
-WC	33 441 (.1)	33 294 (.1)	0 (.0)	0 (.0)	0 (.0)	0 (.0)	0 (.0)
-Self-pay	1 284 476 (3.3)	998 835 (2.9)	278 107 (8.1)	8617 (1.1)	0 (.0)	82.3 (.2)	0 (.0)
-No charge	59 658 (.2)	28 202 (.1)	31 336 (.9)	0 (.0)	0 (.0)	0 (.0)	0 (.0)
-Other	472 437 (1.2)	438 704 (1.3)	32 511 (.9)	0 (.0)	0 (.0)	0 (.0)	0 (.0)
-Unknown/Unanswered	1 180 386 (3.0)	1 057 589 (3.0)	86 173 (2.5)	24 677 (3.3)	0 (.0)	0 (.0)	13 318 (7.6)
Total number of chronic conditions, n (SEM)	1.2 (.3)	1.2 (.4)	1.1 (.6)	.3 (.2)	3.0 (1.0)**	3.0 (.01)	1.3 (.4)	.9006^a
CCI, mean (SEM)	1.5 (.1)	1.5 (.1)	1.6 (.3)	.7 (.2)	.9 (.6)	2.8 (.7)	.8 (.3)	.0248^a

^aAnalysis of variance of the differences among psoriasis patients of different races.

^bX² Test of the differences among psoriasis patients of different races.

WC, Worker’s Compensation; CCI, Charlson Comorbidity Index; **extrapolated based on reference SEM, due to low patient visit sample.

The average CCI for White Only race was 1.5 ± .1; the average CCI for Black/African American Only race was 1.6 ± .3; the average CCI for Asian Only race was .7 ± .2; the average CCI for Native Hawaiian/Pacific Islander Only race was .9 ± .6; the average CCI for American Indian/Alaska Native Only race was 2.8 ± .7; and the average CCI for race listed as Other was .8 ± .3. The most common comorbidities are reported by race in Table 2. Hypertension, Arthritis (unspecified type), Hyperlipidemia, and Diabetes were common comorbidities reported for all races (Table 2).

Table 2.

Top 5 Comorbidities (Aside From Psoriasis) Recorded for Psoriasis Patient Visits Between 2002-2016 and 2018 in NAMCS Database, by Race.

	Top 5 comorbidities
Overall cohort visits	1. Hypertension
	2. Arthritis
	3. Hyperlipidemia
	4. Diabetes
	5. Depression
White only visits	1. Hypertension
	2. Arthritis
	3. Depression
	4. Hyperlipidemia
	5. Diabetes
Black/African american only visits	1. Hyperlipidemia
	2. Hypertension
	3. Arthritis
	4. Migraines
	5. Trochanteric bursitis
Asian only visits	1. Hypertension
	2. Erythroleukemia/Acute erythremia
	3. Allergic rhinitis
	4. Arthritis
	5. Asthma
Native Hawaiian/Pacific islander only visits	1. Hypertension
	2. Ischemic heart disease
	3. Rheumatoid arthritis
	4. Arthritis
	5. Hypothyroidism
American indian/Alaska native only visits	1. Arthritis, diabetes, arteritis unspecified (same count)
American indian/Alaska native only visits	2. Hyperlipidemia, hypertension, depression, arthropathy, acute erythremia/Erythroleukemia (same count)
Other visits	1. Hypertension
	2. Asthma
	3. Obesity
	4. Coronary artery disease, arthritis (same count)

On multivariable linear regression, comorbidity burden, as measured by CCI, was not found to be different in patients with SOC compared to patients of White Only race, after adjusting for level of care, age, sex, and geographic region. (Table 3). Specifically, looking at individual comparisons among races when compared to White patients, Black/African American Only race, American Indian/Alaska Native Only race, Asian Only race, Native Hawaiian/Pacific Islander Only race, and Other race did not have statistically significant differences in comorbidity burden, as measured by CCI (P = .073 for Black/African American Only vs White Only, P = .073 for American Indian/Alaska Native Only vs White Only, P = .435 for Asian Only vs White Only, P = .403 for Native Hawaiian/Pacific Islander Only vs White Only, P = .195 for Other vs White Only).

Table 3.

Multiple Linear Regression Analysis of Association Between CCI and Race in Psoriasis Patients, Adjusting for Insurance Type.

	b Coefficient (95% CI)	P Value
CCI
White only	(Ref)	—
Black/African american only	.20 (-.02-.42)	.073
Asian only	-.11 (-.39-.17)	.435
Native Hawaiian/Pacific islander only	-.37 (-1.25-.50)	.403
American indian/Alaska native only	.93 (-.09-1.94)	.073
Other	-.41 (-1.03-.21)	.195
Sex
Female	(Ref)	—
Male	.01 (-.09-.11)	.844
Age
18-39 years old	(Ref)	—
40-59 years old	.71 (.58-.84)	<.001
≥60 years old	2.64 (2.49-2.80)	<.001
Geographic region
Northeast	(Ref)	—
Midwest	.03 (-.11-.18)	.665
South	.05 (-.09-.20)	.460
West	-.05 (-.19-.10)	.551
Insurance type
Private insurance	(Ref)	—
Medicare	.70 (.56-.85)	<.001
Medicaid	.19 (-.03-.41)	.097
Worker’s compensation	-.04 (-.92-.83)	.924
Self-pay	-.22 (-.48-.05)	.104
No charge	-.27 (-1.15-.61)	.550
Other	.09 (-.35-.53)	.685
Unknown or unanswered	.16 (-.10-.43)	.224
R²	.6738
F (18, 1270)	145.75
Prob > F	<.001

CCI, Charlson Comorbidity Index.

Additionally, we also examined other factors that are associated with comorbidity burden. In this NAMCS study we found that patient visits with an Insurance Type of Medicare were associated with a significantly higher CCI for psoriasis patients than Insurance Type of Private Insurance (P < .001) (Table 3). Also, patient visits with age of 40-59 and age of 60+ were associated with a significantly higher CCI (P < .001 and P < .001, respectively) (Table 3).

In sensitivity analyses, we examined the impact of insurance on differences in comorbidity burden among races. We found that, when the regression did not adjust for insurance, Black/African American Only race was associated with a significantly higher CCI compared to White Only race (P = .037) (Table 4). However, when insurance was added to the model, we did not find any significant differences among the races.

Table 4.

Multiple Linear Regression Analysis of Association Between CCI and Race in Psoriasis Patients.

	b Coefficient (95% CI)	P Value
CCI
White only	1 (ref)	—
Black/African american only	.24 (.01-.46)	.037
Asian only	-.12 (-.41-.17)	.415
Native Hawaiian/Pacific islander only	-.23 (-1.14-.68)	.620
American indian/Alaska native only	.70 (-.34-1.75)	.187
Other	-.43 (-1.07-.21)	.191
Sex
Female	1 (ref)	—
Male	.004 (-.10-.11)	.934
Age
18-39 years old	1 (ref)	—
40-59 years old	.75 (.61-.88)	<.001
≥60 years old	3.00 (2.86-3.14)	<.001
Geographic region
Northeast	1 (ref)	—
Midwest	.07 (-.08-.22)	.366
South	.10 (-.05-.25)	.187
West	-.03 (-.19-.12)	.687
R²	.6472
F (11, 1278)	213.14
Prob > F	<.001

CCI, Charlson Comorbidity Index.

Discussion

Potential differences in comorbidity burden based on race may contribute to differences in psoriasis patient outcomes; this study is among the first to examine the relationship between comorbidities and race in psoriasis patients. Using the NAMCS database, we found no differences in comorbidity burden between psoriasis visits of SOC patients and White patients (Table 3). When insurance is not accounted for, we may see a higher comorbidity burden among Blacks vs Whites (Table 4).

Insurance type has often been used as a proxy for socioeconomic status in a variety of study types, ranging from database studies looking at health outcomes in women with breast cancer to analyses comparing individual clinics in their medication management of coronary artery disease.^14-19 Insurance status can be used to estimate socioeconomic status because it reflects patient ability to overcome the financial barriers to health care.^16,19 The fact that the significant difference in comorbidity burden between Black/African American Only race and White Only race resolves when controlling for insurance type as a proxy for level of care shows that differences in health outcomes in psoriasis patients with SOC are more likely due to factors external to patient race. These findings align with the previously established consensus that race does not affect health due to biologic differences, but rather because race affects a variety of other social factors that then impact health, such as socioeconomic status.^20-25

In our model, we also observed that increasing age correlated with a higher comorbidity burden: patients with an age of 40-59 or 60+ demonstrated a significantly higher comorbidity burden than patients ages 18-39 years old. This may be related to an increased likelihood of developing multiple chronic diseases with increased age,²⁶ which validates our model.

This study’s findings must be considered within the context of the NAMCS database design. The variables for race are overall established by NAMCS and may not be sufficiently granular for evaluation of racial subgroups. For example, the Asian race encompasses a wide variety of racial subgroups, including South Asians, East Asians, and Southeast Asians. Differences in cultural heritages, values, and lifestyles among these subgroups may affect comorbidity burden. Additionally, most of the weighted patient visits contributing to the NAMCS database were for White patients. Future studies can obtain more data for less represented races as well as specify different subsets of race to obtain a comprehensive understanding of the differences in health status of psoriasis patients of various races in the United States.

Conclusion

In conclusion, psoriasis patients with SOC were not found to have differences in comorbidity burden compared to White patients. These results highlight that race itself is not a central determinant of health status for psoriasis patients in the United States. Rather, social factors such as socioeconomic status and access to health care contribute more directly to health status than patient race.

Footnotes

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Authors HP, MYH, KL, PK, DY, EK, and RA have no conflicts of interest to disclose. AWA has served as a research investigator, scientific advisor, and/or speaker to AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

CME Credit

Hannah Peterson, BS, Margaret Y. Huang, BS, Kathryn Lee, BA, Paige Kingston, BS, Danielle Yee, MD, Edwin Korouri, BS, Rosario Agüero, MD, and April W. Armstrong, MD, MPH

ORCID iDs

Danielle Yee

April W. Armstrong

References

Armstrong

Read

. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2020;323(19):1945-1960. doi:10.1001/jama.2020.4006

Takeshita

Chau

Duffin

Goel

. Promoting diversity, equity, and inclusion for psoriatic diseases. J Rheumatol. 2022;49(6 Suppl 1):48-51. doi:10.3899/jrheum.211330

Armstrong

Mehta

Schupp

Gondo

Bell

Griffiths

CEM

. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940-946. doi:10.1001/jamadermatol.2021.2007

Yadav

Yeung

Miller-Monthrope

, et al. Unmet need in people with psoriasis and skin of color in Canada and the United States. Dermatol Ther. 2022;2(11):2401-2413. doi:10.1007/s13555-022-00811-0

Lytvyn

Sachdeva

Mufti

Yeung

. Dermatology: How to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour. Drugs Context. 2022;11:1-12. doi:10.7573/dic.2021-9-3

Kohn

Pourali

Gutierrez

, et al. Mental health outcomes in White patients versus patients with skin of color with psoriasis. Dermatol Online J. 2021;27(5): 1-17. doi:10.5070/D327553606

McKenzie

Brown-Korsah

Syder

Omar

Taylor

Elbuluk

. Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color. Part II: Differences in clinical presentation and disparities in cutaneous disorders in skin of color. J Am Acad Dermatol. 2022;87(6):1261-1270. doi:10.1016/j.jaad.2022.03.067

Shah

Paris

Mellars

Changolkar

Mease

. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open. 2017;3(2):e000588. doi:10.1136/rmdopen-2017-000588

NAMCS/NHAMCS - Scope and Sample Design. Centers for Disease Control and Prevention. Updated 2019-03-04T08:39:55Z. Accessed 26 Novemeber 2022, https://www.cdc.gov/nchs/ahcd/ahcd_scope.htm

10.

NAMCS/NHAMCS - about the Ambulatory Health Care Surveys. Centers for Disease Control and Prevention. Updated 2021-12-30T04:03:32Z. Accessed 26 Novemeber 2022, https://www.cdc.gov/nchs/ahcd/about_ahcd.htm#NAMCS

11.

Charlson

Pompei

Ales

MacKenzie

. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis. 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8

12.

Glasheen

Cordier

Gumpina

Haugh

Davis

Renda

. Charlson comorbidity Index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12(4):188-197.

13.

Charlson

Carrozzino

Guidi

Patierno

. Charlson comorbidity Index: A critical Review of clinimetric properties. Psychother Psychosom. 2022;91(1):8-35. doi:10.1159/000521288

14.

Ayanian

Kohler

Abe

Epstein

. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med. 1993;329(5):326-331. doi:10.1056/NEJM199307293290507

15.

Harnick

Cohen

Schechter

Fuster

Smith

. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease. Am J Cardiol. 1998;81(12):1416-1420. doi:10.1016/s0002-9149(98)00209-4

16.

Shen

Wan

Perlin

. An exploration of the complex relationship of socioecologic factors in the treatment and outcomes of acute myocardial infarction in disadvantaged populations. Health Serv Res. 2001;36(4):711-732.

17.

Rosenbaum

. Medicaid. N Engl J Med. 2002;346(8):635-640. doi:10.1056/NEJM200202213460825

18.

Foraker

Rose

Whitsel

Suchindran

Wood

Rosamond

. Neighborhood socioeconomic status, Medicaid coverage and medical management of myocardial infarction: Atherosclerosis risk in communities (ARIC) community surveillance. BMC Publ Health. 2010;10:632. doi:10.1186/1471-2458-10-632

19.

Mueller

Patil

Boilesen

. The role of uninsurance and race in healthcare utilization by rural minorities. Health Serv Res. 1998;33(3 Pt 1):597-610.

20.

Nguyen

Moser

Chou

. Race and health profiles in the United States: An examination of the social gradient through the 2009 CHIS adult survey. Publ Health. 2014;128(12):1076-1086. doi:10.1016/j.puhe.2014.10.003

21.

Caraballo

Ndumele

Roy

, et al. Trends in racial and ethnic disparities in barriers to timely medical care among adults in the US, 1999 to 2018. JAMA Health Forum. 2022;3(10):e223856. doi:10.1001/jamahealthforum.2022.3856

22.

Shavers

. Measurement of socioeconomic status in health disparities research. J Natl Med Assoc. 2007;99(9):1013-1023.

23.

Williams

Collins

. Racial residential segregation: A fundamental cause of racial disparities in health. Publ Health Rep. 2001;116(5):404-416. doi:10.1093/phr/116.5.404

24.

Williams

Yan

Jackson

Anderson

. Racial differences in physical and mental health: socio-economic status, stress and discrimination. J Health Psychol. 1997;2(3):335-351. doi:10.1177/135910539700200305

25.

Colen

Ramey

Cooksey

Williams

. Racial disparities in health among nonpoor African Americans and Hispanics: The role of acute and chronic discrimination. Soc Sci Med. 2018;199:167-180. doi:10.1016/j.socscimed.2017.04.051

26.

Divo

Martinez

Mannino

. Ageing and the epidemiology of multimorbidity. Eur Respir J. 2014;44(4):1055-1068. doi:10.1183/09031936.00059814

Comorbidity Burden in Psoriasis Patients With Skin of Color

Abstract

Background

Objectives

Methods

Results

Conclusion

Keywords

Introduction

Methods

Results

Discussion

Conclusion

Footnotes

Declaration of Conflicting Interests

Funding

CME Credit

ORCID iDs

References